Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Roxitromycin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Roxitromycin Testmiljö

Roxitromycin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.

  2. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35:589-98.

  3. Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 2006;19:189-92.

  4. Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000;79:234-7.

  5. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  6. Bahat Dinur A, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57:3307-11.

  7. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.

  8. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.

  9. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.

  10. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.

  11. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.

  1. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.
  2. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35:589-98.
  3. Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 2006;19:189-92.
  4. Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000;79:234-7.
  5. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
  6. Bahat Dinur A, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57:3307-11.
  7. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.
  8. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.
  9. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.
  10. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.
  11. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.